Granules India has informed that the work on its 6- million tablet facility has progressed and is at an advance stage. The commercial production from its API plant situated at Bonthapally, Medak District has also commenced. The plant has a manufacturing capacity of 8,000 tpa of Paracetamol. Both these facilities are been being built with a view to obtain international regulatory approvals.

"These backward and forward integrations will help us to offer several generic products in OTC and prescription segments, which strengthen the businesses of global formulation customers," according to C Krishna Prasad, chairman and managing director, Granules India.

He added, "We have prudently invested in people, plants and processes to emerge as a completely integrated and dependable pharmaceutical manufacturing outsourcing company in the pharmaceutical formulation space and we intend to be a 'preferred supplier' to large formulation companies overseas."

Granules are a backward integrated formulations manufacturer for several pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).